A1EAZ
2-[3-[4-(3-chlorophenyl)piperazin-1-yl]propyl]-5-ethyl-4-(2-phenoxyethyl)-1,2,4-triazol-3-one
| Created: | 2024-08-20 |
| Last modified: | 2026-03-04 |
Find Related PDB Entry |
|---|
Find related ligands: |
|---|
Chemical Details | |
|---|---|
| Formal Charge | 0 |
| Atom Count | 65 |
| Chiral Atom Count | 0 |
| Bond Count | 68 |
| Aromatic Bond Count | 12 |
Chemical Component Summary | |
|---|---|
| Name | 2-[3-[4-(3-chlorophenyl)piperazin-1-yl]propyl]-5-ethyl-4-(2-phenoxyethyl)-1,2,4-triazol-3-one |
| Synonyms | Nefazodone |
| Systematic Name (OpenEye OEToolkits) | 2-[3-[4-(3-chlorophenyl)piperazin-1-yl]propyl]-5-ethyl-4-(2-phenoxyethyl)-1,2,4-triazol-3-one |
| Formula | C25 H32 Cl N5 O2 |
| Molecular Weight | 470.007 |
| Type | NON-POLYMER |
Chemical Descriptors | |||
|---|---|---|---|
| Type | Program | Version | Descriptor |
| SMILES | CACTVS | 3.385 | CCC1=NN(CCCN2CCN(CC2)c3cccc(Cl)c3)C(=O)N1CCOc4ccccc4 |
| SMILES | OpenEye OEToolkits | 2.0.7 | CCC1=NN(C(=O)N1CCOc2ccccc2)CCCN3CCN(CC3)c4cccc(c4)Cl |
| Canonical SMILES | CACTVS | 3.385 | CCC1=NN(CCCN2CCN(CC2)c3cccc(Cl)c3)C(=O)N1CCOc4ccccc4 |
| Canonical SMILES | OpenEye OEToolkits | 2.0.7 | CCC1=NN(C(=O)N1CCOc2ccccc2)CCCN3CCN(CC3)c4cccc(c4)Cl |
| InChI | InChI | 1.06 | InChI=1S/C25H32ClN5O2/c1-2-24-27-31(25(32)30(24)18-19-33-23-10-4-3-5-11-23)13-7-12-28-14-16-29(17-15-28)22-9-6-8-21(26)20-22/h3-6,8-11,20H,2,7,12-19H2,1H3 |
| InChIKey | InChI | 1.06 | VRBKIVRKKCLPHA-UHFFFAOYSA-N |
Drug Info: DrugBank
DrugBank data are sourced from datasets licensed under a Creative Common's Attribution-NonCommercial 4.0 International License
| DrugBank ID | DB01149 |
|---|---|
| Name | Nefazodone |
| Groups |
|
| Description | Nefazodone hydrochloride (trade name Serzone) is an antidepressant drug marketed by Bristol-Myers Squibb. Its sale was discontinued in 2003 in some countries, due to the small possibility of hepatic (liver) injury. Drug-induced hepatic injuries were associated with an risk of elevated need for a liver transplant, or even death, with the incidence of severe liver damage was shown to be approximately 1 in 250,000 to 300,000 patient-years. On May 20, 2004, Bristol-Myers Squibb discontinued the sale of Serzone in the United States. |
| Synonyms |
|
| Brand Names |
|
| Indication | For the treatment of depression. |
| Categories |
|
| ATC-Code | N06AX06 |
| CAS number | 83366-66-9 |
Drug Targets
DrugBank data are sourced from datasets licensed under a Creative Common's Attribution-NonCommercial 4.0 International License
| Name | Target Sequence | Pharmacological Action | Actions |
|---|---|---|---|
| 5-hydroxytryptamine receptor 2A | MDILCEENTSLSSTTNSLMQLNDDTRLYSNDFNSGEANTSDAFNWTVDSE... | unknown | antagonist |
| 5-hydroxytryptamine receptor 2C | MVNLRNAVHSFLVHLIGLLVWQSDISVSPVAAIVTDIFNTSDGGRFKFPD... | unknown | antagonist |
| Sodium-dependent serotonin transporter | METTPLNSQKQLSACEDGEDCQENGVLQKVVPTPGDKVESGQISNGYSAV... | unknown | inhibitor |
| 5-hydroxytryptamine receptor 1A | MDVLSPGQGNNTTSPPAPFETGGNTTGISDVTVSYQVITSLLLGTLIFCA... | unknown | antagonist |
| Sodium-dependent noradrenaline transporter | MLLARMNPQVQPENNGADTGPEQPLRARKTAELLVVKERNGVQCLLAPRD... | unknown | inhibitor |
| View More | |||
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison
T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS.
Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682














